A recent paper in the scientific journal Nucelar Medicine and Biology (33; 271-279, 2006)
reports the first experiences with a novel alpha-particle based anti CD-20 radioimmunoconjugate.
Radioimmunotherapy has proven clinically effective in patients with non-Hodgkins lymphoma. Trials have so far been performed with beta-emitting isotopes. In contrast to ß-emitters, the shorter range and high linear energy transfer of alpha particles allow for more efficient and selective killing of individually targeted tumor cells. The alpha emitting radioimmunoconjugate 227Th-DOTA-p-benzyl-rituximab is a new potential anti-lymphoma agent that might overcome some of these difficulties is currently in the translational phase of testing. Therapeutic studies in tumor-bearing nude mice will be published soon. The aim is to start clinical Phase-I testing.